Colorado Burden of Disease, Injuries and Risk Factors, 1990-2019: A Sub-Analysis of the Global Burden of Disease Study.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
28 12 2021
Historique:
received: 26 06 2021
revised: 14 12 2021
accepted: 23 12 2021
entrez: 11 1 2022
pubmed: 12 1 2022
medline: 27 1 2022
Statut: epublish

Résumé

(1) Background: Health disparities across the United States (U.S.) are increasing. Large variations in risk factors and health outcomes have been described among states from the U.S. (2) AIM. This study aims to describe health trends in morbidity, mortality, and risk factors from 1990 to 2019 in the State of Colorado. (3) Methods: We describe the measures of health loss for 286 causes of death, 369 diseases and injuries, and 87 risk factors for the state of Colorado from the Global Burden of Disease project estimates between 1990 to 2019. (4) Results: We found that 21,171 and 40,724 deaths were estimated in 1990 and 2019, respectively, in Colorado. The leading cause of death, in both sexes, in 1990 and 2019 was ischemic heart disease (IHD). The top leading disability-adjusted life years (DALY) diagnoses were IHD, followed by low back pain, chronic obstructive pulmonary disease, and opioid use disorder. In 2019, the top risk factors by DALYs in Colorado were smoking, drug use, high body mass index (BMI), alcohol use, high fasting plasma glucose, and high systolic blood pressure. (5) Conclusion: Non-communicable diseases and their related risk factors are the top leading causes of DALYs in Colorado. Findings support the need for policies to prevent non-communicable diseases, with special attention to musculoskeletal disorders and interventions to reduce tobacco, alcohol, and drug use.

Identifiants

pubmed: 35010548
pii: ijerph19010288
doi: 10.3390/ijerph19010288
pmc: PMC8744865
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Int J Drug Policy. 2019 Jun;68:46-53
pubmed: 30991301
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Int J Prev Med. 2016 Jan 11;7:7
pubmed: 26941908
JAMA. 2018 Apr 10;319(14):1444-1472
pubmed: 29634829
Lancet. 2018 Jun 9;391(10137):2368-2383
pubmed: 29573872
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Lancet. 2019 May 11;393(10184):1958-1972
pubmed: 30954305
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Lancet. 2019 Aug 24;394(10199):685-696
pubmed: 31448740
Lancet. 2018 Nov 3;392(10158):1647-1661
pubmed: 30497795

Auteurs

Jen Roux (J)

Colorado School of Public Health, Colorado State University, 1601 Campus Delivery, Fort Collins, CO 80523, USA.
Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523, USA.

David Rojas-Rueda (D)

Colorado School of Public Health, Colorado State University, 1601 Campus Delivery, Fort Collins, CO 80523, USA.
Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH